Hematologic Malignancies: Multiple Myeloma | Special Reports

Dr. Robert Z Orlowski on the Importance of the Phase III SWOG S0777 Trial

December 15, 2015

Clinical Articles

Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

Elotuzumab Benefits Level Out in 3-Year Myeloma Data

December 14, 2015

Clinical Articles

A triplet of elotuzumab, lenalidomide, and dexamethasone produced sustained improvements in both progression-free survival and overall survival in patients with relapsed/refractory multiple myeloma, according to a 3-year analysis of the phase III ELOQUENT-2 trial.

Bortezomib Triplet Emerges as the New Standard of Care in Patients With Untreated Multiple Myeloma

December 14, 2015

Clinical Articles

The SWOG S0777 trial data shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

New Data Suggests Role for CAR Treatment Post-Transplant in Advanced B-cell Cancers

December 12, 2015

Clinical Articles

Gene therapy has potential to deliver lasting remissions in patients with advanced B-cell malignancies who have undergone allogeneic hematopoietic stem cell transplant, according to research presented by James N. Kochenderfer, MD.

Ixazomib Triplet Showcases PFS Increases in Myeloma

December 12, 2015

Clinical Articles

An oral treatment combination of ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival in comparison to lenalidomide and dexamethasone alone for relapsed/refractory multiple myeloma.